Axonics, Inc.
Axonics, Inc., a medical technology company, engages in the development and commercialization of sacral neuromodulation (SNM) systems. The company's SNM systems are used to treat patients with overactive bladder, including urinary urge incontinence and u…
Medical - Devices
US, Irvine [HQ]
FA
Fundamental Analysis · Most Recent Quarter
A dedicated fundamental analysis might help you to get a quick overview
of the
financial stability. It is important to understand the
FA Algorithm
and the criterias before valuing it as a top-tier resource.
1
Financial Health
| Metric | Q4 | Q1 | Δ in % | |
|---|---|---|---|---|
| Current Ratio | -7.12 | 9.96 | 10.73 | |
| Debt/Assets | n.A. | n.A. | n.A. | |
| Debt/Equity | n.A. | n.A. | n.A. | |
| Net Debt/EBITDA | 160.14 | 24.53 | -9.43 | |
| Naive Interpretation | member | |||
2
Per Share
| Metric | Q4 | Q1 | Δ in % | |
|---|---|---|---|---|
| Book Value | -4.59 | 12.31 | 12.91 | |
| Cash | -6.41 | 6.53 | 6.98 | |
| Capex | -127.04 | -0.06 | -0.03 | |
| Free Cash Flow | 175.89 | -0.24 | 0.09 | |
| Revenue | -19.20 | 1.79 | 2.22 | |
| Naive Interpretation | member | |||
3
Profitability
| Metric | Q4 | Q1 | Δ in % | |
|---|---|---|---|---|
| Gross Margin | 3.28 | 0.76 | 0.73 | |
| Operating Margin | 400.96 | -0.21 | 0.04 | |
| ROA | 192.49 | -0.03 | < 0.005 | |
| ROE | 195.57 | -0.03 | 0.01 | |
| ROIC | 337.87 | -0.04 | < 0.005 | |
| Naive Interpretation | member | |||
4
Valuation
The "Valuation Entry" for the Focus of AXNX is permitted for members.
5
Growth
The "Growth Entry" for the Focus of AXNX is permitted for members.
6
Leverage & Liquidity